Australian Speedrun Marathon 2022 (ASM2022) is back! Australia’s largest, longest running speedrunning event starts on Thursday 13th July with the finale on Sunday 17th July. Game On Cancer will be the recipient of this massive fundraising effort.
Game On Cancer is an initiative of Cure Cancer which is an Australian-based charity dedicated entirely to funding early career cancer researchers. To date it has provided over 540 grants to young scientists, many of them going on to become global leaders.
HyperX Joins As A Major Partner
Leading gaming peripheral maker HyperX will be joining ASM2022 and Game On Cancer as a major partner. They will be supporting the production the event as well as promoting ASM2022 to their community.
Ethan Levy, Coordinator at AusSpeedruns, said “AusSpeedruns greatly welcomes the support of HyperX for our 2022 events. Having the support of fantastic organisations like HyperX helps us achieve our core goals of building a stronger speedrunning community here in Australia, and raising more money for wonderous causes like Game On Cancer.”
“It is important HyperX is an active citizen and has a positive impact on our communities. The team is proud to be the major sponsor for Cure Cancer and AusSpeedruns 2022 events in Australia. It makes sense for us to support causes like this that do such amazing work and inspire the good in the gaming community, aligning with the concept that ‘We’re All Gamers’,” said HyperX.
Funds Going To Game On Cancer
Shane Bailey, Head of Gaming & Streaming at Cure Cancer, said, “Our team is thrilled to be partnering with the AusSpeedruns community once again, this time for ASM2022. Funds raised during the marathon will support life-saving cancer research and having the support of HyperX will only help us make an even bigger difference together.”
The full schedule for ASM2022 can be found on the AusSpeedruns website. The event can be watched live from 10am AEST on Wednesday the 13th July on the AusSpeedruns Twitch channel. Donations can be made on the ASM2022 Tiltify page.